Midcareer Investigator Award in Patient-Oriented Research (Parent K24)

以患者为导向的研究中的职业生涯中期研究员奖（家长 K24）

• 批准号: 10369610
• 负责人: Mark Sebastian Sulkowski
• 金额: $ 12.2万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-15 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10369610
• 关键词: AIDS clinical trial group; Academy; Acute Hepatitis C; African American population; Alcoholic steatohepatitis; Award; Cardiovascular system; Caring; Cells; Centers for Disease Control and Prevention (U.S.); Cessation of life; Chronic Hepatitis C; Clinic; Clinical; Clinical Investigator; Clinical Management; Clinical Research; Collaborations; Communicable Diseases; Communities; Comparative Study; Data; Development; Disease; Doctor of Medicine; Drug usage; Drug user; Elderly; Epidemic; Funding; Genotype; Goals; HIV; HIV Infections; HIV/HCV; Health; Hepatitis; Hepatitis B Infection; Hepatitis B Virus; Hepatitis C; Hepatitis C Incidence; Hepatitis C Therapy; Hepatitis C Transmission; Hepatitis C co-infection; Hepatitis C virus; Hepatocyte; Immune; Immune response; Incentives; Individual; Infection; Injecting drug user; Injections; Intervention; Kidney; Kidney Transplantation; Lasers; Link; Liver; Liver Failure; Liver diseases; Malignant Neoplasms; Medicine; Mentors; Mentorship; Microdissection; Mid-Career Clinical Scientist Award (K24); Midcareer Investigator Award in Patient-Oriented Research; Network-based; Opioid; Osteomyelitis; Outcome; Parents; Participant; Persons; Pilot Projects; Population; Prevalence; Prevention; Publications; Randomized; Reporting; Research; Research Personnel; Resource-limited setting; Risk; Role; Science; Social Network; Suboxone; Substance abuse problem; Testing; Time; Tissues; Toxicology; Training; Translations; United States; United States National Institutes of Health; Universities; Urine; Virus Diseases; Work; addiction; barrier to care; base; bone; cardiovascular infection; career; co-infection; cost; curative treatments; disorder risk; effectiveness evaluation; financial incentive; indexing; infection risk; innovation; intrahepatic; kidney infection; liver transplantation; medical schools; member; mortality; non-alcoholic; nonalcoholic steatohepatitis; novel; opioid injection; opioid treatment program; opioid use disorder; pathogen; patient population; peer coaching; peer support; prevent; preventive intervention; professor; programs; recruit; substance use; treatment as usual; young adult

The current proposal is a competitive renewal of a K24 Midcareer Investigator Award in Patient- oriented research for Mark S. Sulkowski, MD of the Johns Hopkins University School of Medicine. Dr. Sulkowski is an infectious disease-trained clinical investigator at Johns Hopkins University where he is a Professor of Medicine and directs a highly productive clinical research program focused on the intersection of HIV, hepatitis C virus (HCV), and substance use. His research is supported by an NIH R01 and the NIH-funded AIDS Clinical Trials Group (ACTG); he serves as the Chair of the ACTG Hepatitis Transformative Sciences Group. During his time at Johns Hopkins, he has made substantial scientific contributions to the development of revolutionary HCV treatments. His work has also significantly advanced the clinical management of HCV disease in persons living with HIV infection. Current HCV therapies can cure more than 95% of individuals who are successfully linked to care and initiate treatment including individuals with HIV coinfection and those who use drugs. However, in 2013, the annual HCV-related mortality surpassed the combined number of deaths from 60 other infections reported to the Centers for Disease Control, including HIV. While HCV-related deaths are most common in older adults with long-standing HCV, the United States has also witnessed the resurgence of new HCV infections in young adults as the result of the injection opiate epidemic. In 2017, the National Academy of Medicine concluded that treating all persons with chronic HCV would reduce new infections by 90% and HCV-related deaths by 65% by 2030. To achieve this ambitious goal, strategies to prevent and cure HCV in persons who inject drugs are urgently needed. Renewal of this K24 is critical to Dr. Sulkowski's plan to investigate such strategies. Project aims include new collaborative research to evaluate the role of injection networks in HCV treatment and prevention and to assess the feasibility of HCV clinic-based buprenorphine-naloxone to increase concurrent treatment of HCV and opiate use disorders. For progress to be made toward achieving the Academy's goals, young clinical investigators are also needed. During the initial K24 period, Dr. Sulkowski had over 67 publications; the majority of which included young investigators who are pursuing careers in academic research. Renewal of this K24 award is critical to his desire to continue to mentor junior researchers in the key fields of HIV and HCV and to continue to evolve his research through new training in substance abuse research. The protected time afforded by this award is essential to Dr. Sulkowski achieving these goals.

目前的建议是K24中期职业研究者奖的竞争性更新

项目成果

Senior Center-Based Hepatitis C Screening in Baltimore.

• DOI: 10.1093/ofid/ofv217
• 发表时间: 2016-01
• 期刊: Open forum infectious diseases
• 影响因子: 4.2
• 作者: Falade-Nwulia O;Irvin R;McAdams-Mahmoud A;Mehta SH;Niculescu A;Lasola J;Baker D;Eppel A;Chaulk P;Page KR;Sulkowski M;Thomas D
• 通讯作者: Thomas D

No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.

没有证据表明接受雷迪帕韦-索磷布韦治疗丙型肝炎病毒感染的患者中乙型肝炎病毒重新激活。

• DOI: 10.1093/cid/ciw507
• 发表时间: 2016
• 期刊: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
• 作者: Sulkowski,MarkS;Chuang,Wan-Long;Kao,Jia-Horng;Yang,JennyC;Gao,Bing;Brainard,DianaM;Han,Kwang-Hyub;Gane,Edward
• 通讯作者: Gane,Edward

Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine.

与使用受控人体感染试验开发丙型肝炎病毒疫苗的可能性相关的伦理和实践问题。

• DOI: 10.1093/cid/ciaa640
• 发表时间: 2020
• 期刊: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
• 作者: Cox,Andrea;Sulkowski,Mark;Sugarman,Jeremy
• 通讯作者: Sugarman,Jeremy

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.

BMS-936558的随机，双盲，安慰剂对照的评估，一种完全人类的单克隆抗体，对慢性丙型肝炎病毒感染的患者，对程序性死亡-1（PD-1）。

• DOI: 10.1371/journal.pone.0063818
• 发表时间: 2013
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Gardiner D;Lalezari J;Lawitz E;DiMicco M;Ghalib R;Reddy KR;Chang KM;Sulkowski M;Marro SO;Anderson J;He B;Kansra V;McPhee F;Wind-Rotolo M;Grasela D;Selby M;Korman AJ;Lowy I
• 通讯作者: Lowy I

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

• DOI: 10.1111/jvh.12173
• 发表时间: 2013-11
• 期刊: Journal of viral hepatitis
• 影响因子: 2.5
• 作者: Afdhal NH;Zeuzem S;Schooley RT;Thomas DL;Ward JW;Litwin AH;Razavi H;Castera L;Poynard T;Muir A;Mehta SH;Dee L;Graham C;Church DR;Talal AH;Sulkowski MS;Jacobson IM;New Paradigm of HCV Therapy Meeting Participants
• 通讯作者: New Paradigm of HCV Therapy Meeting Participants